At the beginning of February 2021, 289 experimental vaccines were in development. So far, 20 candidates have reached the critical phase 3 of clinical trials, and five have received authorization for use by one of the stringent regulatory authorities on the World Health Organisation’s (WHO) list.

A recent health policy opinion piece, published in The Lancet on 12 February, reviews four interconnected challenges to the success of vaccination schemes: production, affordability, allocation, and deployment of the vaccines.

Read the full article at medicalnewstoday.com